by Peter Ciszewski | May 18, 2020
The U.S. Food and Drug Administration (FDA) has approved Pomalyst (pomalidomide) for treating patients Kaposi sarcoma, a rare skin cancer sometimes seen in people with AIDS or other immunocompromised conditions. More specifically, the drug is indicated to treat...
by Peter Ciszewski | May 15, 2020
Ozlem Goker-Alpan, MD, provides a summary of research presented at WORLDSymposium 2020 focused on Fabry disease. This video resource is part of the CME activity Fabry Disease Highlights from WORLDSymposium 2020, which is supported by an educational grant from...
by Peter Ciszewski | May 14, 2020
Rami Levin, CEO of Saniona, a pharmaceutical company focused on rare neurological diseases describes Prader-Willi syndrome (PWS) and the latest clinical data involving PWS patients given Tesomet (tesofensine + metoprolol). PWS is a genetic condition that leads...
by Peter Ciszewski | May 13, 2020
Michael Snape, PhD, Chief Scientific Officer at AMO Pharma describes the history of his company and its current pipeline that is largely focused on rare neurodevelopmental conditions, including congenital myotonic dystrophy, Phelan-McDermid syndrome, and Rett...
by Peter Ciszewski | May 12, 2020
Riam Shammaa, MD, Founder INTELLiSTEM Technologies, lists three factors that are important to understand when developing a vaccine for COVID-19. The three factors mentioned by Dr. Shammaa are 1) understand that the virus is mutating, 2) have a cellular response...
